Denileukin Diftitox

Cutaneous Melanoma

National Cancer Institute (NCI)protein_peptidePhase 2Dormant

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 47/ 100
Competitive Position: 81/ 100

Competitive context

142 Active assets in the Cutaneous Melanoma cohort.

Asset / Sponsor	Phase	Rating
Alpha-Interferon MIPO Clinic	Phase 3	BBB
Dacarbazine Linnaeus Therapeutics, Inc.	Phase 3	BBB
TIL City of Hope Medical Center	Phase 2	BBB
Tyrosinase Peptide University of Southern California	Phase 3	BBB
Cis-Diamminedichloroplatinum Ii MIPO Clinic	Phase 3	BBB

View all 50 →

Same molecule, other indications

Denileukin Diftitox is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaDormant

BB

Indicative · Phase 4

68 / 100

mycosis fungoidesDormant

B

Indicative · Phase 4

62 / 100

Sezary syndromeDormant

B

Indicative · Phase 4

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.